Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo M odels of Cohesin-Mutant Myeloid Diseases

Mounica Vallurupalli, MD, Rebecca Gorelov, BS, Jacqueline S Garcia, MD, Elizabeth A Morgan, MD, Benjamin Ebert, MD, Zuzana Tothova, MD PhD

Blood (2019) 134 (Supplement_1): 560.

https://doi.org/10.1182/blood-2019-130308

Published: 2019

Journal Articles

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Vanessa Kohl, MSc, Susanne Brendel, MTA, Johanna Flach, PhD, Helga Kleiner, MTA, Christel Weiss, PhD, Wolfgang Seifarth, PhD, Daniel Nowak, MD, Wolf-Karsten Hofmann, MD PhD, Alice Fabarius, PhD, Henning D. Popp

Blood (2019) 134 (Supplement_1): 5056.

https://doi.org/10.1182/blood-2019-122672

Published: 2019

Journal Articles

High Expression of BCAT1 promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Jie Jin, PhD, Jie Jin, PhD, Jiajia Pan, Yungui Wang, PhD, Shujuan Huang, Shihui Mao, Qing Ling, Jinghan Wang, MD PhD, Chenying Li

Blood (2019) 134 (Supplement_1): 5041.

https://doi.org/10.1182/blood-2019-125221

Published: 2019

Journal Articles

Lw-218, a New Flavonoid Compound, Exerts Anti-T-Cell Malignancies Effects Via Autophagy-Mediated Apoptosis

Po Hu, Hui Li, Bao-An Chen, Hua Tang, Zheng Ge, MD PhD, Jing Zhang, Hui Hui, Qing-long Guo

Blood (2019) 134 (Supplement_1): 5756.

https://doi.org/10.1182/blood-2019-122409

Published: 2019

Journal Articles

PARP Inhibition Sensitize BCR-ABL1 Positive Cel

Haruka Hiroki, MD, Masatoshi Takagi, MD PhD, Yuko Ishi, MD, Jinhua Piao, Tomohiro Morio, MD PhD

Blood (2019) 134 (Supplement_1): 3367.

https://doi.org/10.1182/blood-2019-127853

Published: 2019

Journal Articles

Targeting DNA Damage and Repair in Acute Myeloid Leukemia Carrying Internal Tandem Duplication of Fms-like Tyrosine Kinase 3 (FLT3-ITD) - a Mechanistic Study

Ka Lam Nelson Ng, PhD, Claire Lynn, Thomas Wing Yan Leung, Eric Chi Wai So, PhD, Anskar Yu Hung Leung, MD PhD

Blood (2019) 134 (Supplement_1): 1261.

https://doi.org/10.1182/blood-2019-129472

Published: 2019

Journal Articles

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Kinjal Shah, MS, Julhash U. Kazi, PhD

Blood (2019) 134 (Supplement_1): 2752.

https://doi.org/10.1182/blood-2019-129823

Published: 2019

Journal Articles

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Virginia Campos Silvestrini, BSc, MSc, Eduardo M Rego, MD PhD, Vitor Marcel Faca, PhD, João Agostinho Machado-Neto, PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 2689.

https://doi.org/10.1182/blood-2019-132129

Published: 2019

Journal Articles

Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients

Diletta Fontana, PhD, Daniele Ramazzotti, PhD, Andrea Aroldi, MD, Antonio Niro, MS, Luca Massimino, PhD, Delphine Rea, MD, Fabio Stagno, MD, Bruno Martino, MD, Leonardo Campiotti, MD, Giovanni Caocci, MD, Elena Maria Elli, MD, Monica Fumagalli, MD, Fabio Ciceri, MD, Rocco Piazza, MD PhD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1714.

https://doi.org/10.1182/blood-2019-126467

Published: 2019

Journal Articles

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Yihong Guan, PhD, Anand D. Tiwari, PhD, James G Phillips, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Daniel Lindner, MD PhD, Manja Meggendorfer, PhD, Mohamed Abazeed, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 880.

https://doi.org/10.1182/blood-2019-131920

Published: 2019

Journal Articles

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

Pu Zhang, Lindsey Brinton, PhD, James S. Blachly, MD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2019) 134 (Supplement_1): 2072.

https://doi.org/10.1182/blood-2019-129036

Published: 2019

Journal Articles

Proteomic Landscape of Acute Leukemia: A Comparison between ALL and AML in Adults

Fieke W Hoff, BSc, Yihua Qiu, Wendy Hu, PhD, Amina A Qutub, PhD, Eveline S. de Bont, MD PhD, Terzah M Horton, MD PhD, Steven M. Kornblau, MD

Blood (2019) 134 (Supplement_1): 1461.

https://doi.org/10.1182/blood-2019-123470

Published: 2019

Journal Articles

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Daniele Caracciolo, MD, Giada Juli, PhD, Francesca Scionti, PhD, Gaetanina Golino, PhD, Mariamena Arbitrio, MD, Emanuela Altomare, PhD, Katia Todoerti, PhD, Katia Grillone, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 3107.

https://doi.org/10.1182/blood-2019-128245

Published: 2019

Journal Articles

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics

Nefeli Giannakopoulou, Marianna Politou, MD, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitris Korakakis, Maria Efstathopoulou, Theodora Kassi, Christina-Nefeli Kontandreopoulou, Katerina Zoi, PhD, Andreas Giannopoulos, BSc, MSc, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Nora-Athina Viniou, MD

Blood (2018) 132 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2018-99-116660

Published: 2018

Journal Articles

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Aksinija A Kogan, BS, MS, Michael Topper, BS, Susannah C Shissler, BS, Michael S Lee, BS, Dominique R Bollino, BS, Eun Yong Choi, Rena G Lapidus, PhD, Li Li, MD PhD, Donald Small, MD PhD, Maria R. Baer, MD, Tonya J Webb, PhD, Stephen Baylin, MD, Feyruz V. Rassool, BSc, PhD

Blood (2018) 132 (Supplement 1): 3886.

https://doi.org/10.1182/blood-2018-99-117294

Published: 2018

Journal Articles

STAG2 Mutations Alter Cohesin Ring Function and Provide Therapeutic Vulnerabilities in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 940.

https://doi.org/10.1182/blood-2018-99-117480

Published: 2018

Journal Articles

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Blood (2018) 132 (Supplement 1): 769.

https://doi.org/10.1182/blood-2018-99-118047

Published: 2018

Journal Articles

Analysis of BRCA1 and BRCA2 Mutations and Gene Expression in Hematological Malignancies - Implications for Differential Involvement in Pathogenesis of Lymphoid Neoplasms

Anna Stengel, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Wolfgang Kern, MD, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2018) 132 (Supplement 1): 1348.

https://doi.org/10.1182/blood-2018-99-111826

Published: 2018

Journal Articles

Targeting PARP1 As an Effective Treatment for Diffuse Large B-Cell Lymphoma with High Level of γH2AX

Yanyan Liu, Peipei Zhang, Jiuyang Zhang, Wenping Zhou, Jialin Ma, Xinyang Zhao, PhD

Blood (2018) 132 (Supplement 1): 5799.

https://doi.org/10.1182/blood-2018-99-117590

Published: 2018

Journal Articles

PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions

Margaret Nieborowska-Skorska, Paulina Podszywalow-Bartnicka, Silvia Maifrede, Bac Viet Le, Monika Toma, Peter Valent, Tomasz Sliwinski, Wayne Childers, Katarzyna Piwocka, Alexei Tulin, Tomasz Skorski, MD PhD

Blood (2018) 132 (Supplement 1): 3000.

https://doi.org/10.1182/blood-2018-99-115041

Published: 2018

NARROW

Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo M odels of Cohesin-Mutant Myeloid Diseases

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

High Expression of BCAT1 promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Lw-218, a New Flavonoid Compound, Exerts Anti-T-Cell Malignancies Effects Via Autophagy-Mediated Apoptosis

PARP Inhibition Sensitize BCR-ABL1 Positive Cel

Targeting DNA Damage and Repair in Acute Myeloid Leukemia Carrying Internal Tandem Duplication of Fms-like Tyrosine Kinase 3 (FLT3-ITD) - a Mechanistic Study

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

Proteomic Landscape of Acute Leukemia: A Comparison between ALL and AML in Adults

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

STAG2 Mutations Alter Cohesin Ring Function and Provide Therapeutic Vulnerabilities in Acute Myeloid Leukemia

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Analysis of BRCA1 and BRCA2 Mutations and Gene Expression in Hematological Malignancies - Implications for Differential Involvement in Pathogenesis of Lymphoid Neoplasms

Targeting PARP1 As an Effective Treatment for Diffuse Large B-Cell Lymphoma with High Level of γH2AX

PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only